Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience from the Spanish Group of Hematopoietic Transplant (GETH-TC)

• Published in: Blood 2021-11, Vol.138 (Supplement 1), p.1798-1798
• Main Authors: Bailen, Rebeca, Vicario, Jose Luis, Herruzo, Beatriz, Guerra, Luisa Maria, Vallés, Ana, Esquirol, Albert, Fonseca, Marta, Solán, Laura, Sanchez Vadillo, Irene, Bento, Leyre, Pérez Martínez, Ariadna, Torrent, Anna, Zanabili, Joud, Calbacho, Maria, Alenda, Raquel, Moreno, Miguel Ángel, Gago, Beatriz, Chinea, Anabelle, García-Cadenas, Irene, Boix-Giner, Francisco, López Lorenzo, José Luis, Humala, Karem, Acosta-Fleitas, Cynthia, Sampol, Antonia, Oarbeascoa, Gillen, Anguita, Javier, Diez-Martin, Jose L., Kwon, Mi
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2021-150992

Background. Donor specific antibodies (DSAs) are preformed IgG antibodies with specificity against HLA molecules not shared with the donor that can lead to graft failure (GF) in the setting of mismatched HSCT. The aim of this study is to report the experience of the Spanish Group of Hematopoietic Transplant (GETH-TC) in patients with DSAs undergoing haplo-HSCT. Methods. Patients undergoing haplo-HSCT in centers from the GETH-TC from 2013 to 2021 were included in the study. DSAs were analyzed with a solid-phase single-antigen immunoassay (Luminex®); monitoring was performed prior to desensitization, prior to infusion and after infusion. Desensitization strategies used depended on center experience, immunofluorescence intensity, complement fixation and type of antibodies. Results. 59 haplo-HSCT with DSAs were performed in 57 patients in 13 centers. Characteristics of the population are shown in Table 1. 53 (93%) patients were female (91% with prior pregnancies). All patients lacked a suitable alternative donor. 51 (89%) received peripheral blood as stem cell source. Conditioning was myeloablative in 58% and all patients received post-transplant cyclophosphamide based GVHD prophylaxis; 3 (5%) patients received also ATG. 28 (49%) patients presented anti-HLA class I DSAs 22 of them with >5000MFI), 14 (25%) presented anti-HLA class II (6 with >5000MFI) and 15 (26%) presented both anti-HLA class I and II DSAs (13 with >5000MFI). Five patients did not receive desensitization treatment, 4 of them with